Combination Study of Guadecitabine and Pembrolizumab.
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110) a Second
Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with
Refractory Solid Tumours. The investigators will be investigating the safety and toxicity of
the combination.
Phase:
Phase 1
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Institute of Cancer Research, United Kingdom Merck Sharp & Dohme Corp.